Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could fewer injections control wet AMD? new study tests faricimab's staying power

NCT ID NCT06890026

Disease control Sponsor: Rigshospitalet, Denmark Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 742 people newly diagnosed with wet age-related macular degeneration (nAMD) who received 3 monthly injections of faricimab (Vabysmo) instead of the usual 4. The goal was to see how long the effect lasted before another injection was needed. Researchers tracked how many weeks passed after the third injection until the next treatment, aiming to reduce the burden of frequent eye injections.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Faricimab (Vabysmo) injection
What this could lead to
If successful, this could show that 3 loading doses of faricimab are enough to control nAMD, potentially reducing the number of injections patients need.
What could go wrong
This is a completed observational study, not a controlled trial, so results may not apply to all patients. The shorter loading regimen might not work as well as the recommended 4 doses.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

742 people

The number who actually took part.

Started

Nov 2024

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients from the Capital Region of Denmark.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria * Age of 50 years or older. * Treatment-naïve patients diagnosed with nAMD who have received a loading dose with intravitreal faricimab between November 1, 2023, and August 31, 2024. * Follow-up data available until the next subsequent faricimab injection after the loading dose, OR if no injections were indicated following the loading dose, follow-up data for at least 180 days. Exclusion criteria * History of previous anti-VEGF treatment. * Neovascular conditions other than AMD (e.g., choroidal neovascularization due to other causes) or co-existence of other retinal disease in the study eye. * Intraocular surgery in the study eye during the loading dose or prior to the first follow-up visit after the loading dose. * Poor baseline BCVA defined as \<0.1 Snellen (\>1.0 logMAR) * Deviation of ± 2 weeks from the planned loading dose interval of 4 weeks.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Neovascular age-related macular degeneration (NAMD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Neovascular age-related macular degeneration (NAMD) Treatment-naïve

Contacts and locations

Locations

  • Department of Ophthalmology, Rigshospitalet

    Glostrup Municipality, 2600, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.